PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
Background and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in cholesterol homeostasis by regulating low-density lipoprotein (LDL) receptor levels. Despite its known effects on cholesterol metabolism, the role of PCSK9 in cardiac function, especially post-myocardial...
Saved in:
| Main Authors: | Simon Rauterberg, Carmen Härdtner, Jennifer Hein, Paola Schrepf, Remi Peyronnet, Christoph Koentges, Tamara A. Vico, Carolin Ehlert, Bianca Dufner, Diana Lindner, Constantin von zur Mühlen, Dennis Wolf, Dirk Westermann, Ingo Hilgendorf, Alexander von Ehr |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1463844/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01) -
PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01) -
PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01) -
New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01) -
Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)